IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Follow-Up Questions
Who is the CEO of IO Biotech Inc?
Dr. Mai-Britt Zocca is the President of IO Biotech Inc, joining the firm since 2015.
What is the price performance of IOBT stock?
The current price of IOBT is $0.8738, it has increased 4.18% in the last trading day.
What are the primary business themes or industries for IO Biotech Inc?
IO Biotech Inc belongs to Biotechnology industry and the sector is Health Care
What is IO Biotech Inc market cap?
IO Biotech Inc's current market cap is $57.5M
Is IO Biotech Inc a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for IO Biotech Inc, including 3 strong buy, 7 buy, 1 hold, 0 sell, and 3 strong sell
